Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 600,356	$ 373,173
Accounts receivable, net of allowances of approximately $4.0 million and $17.6 million at September 30, 2016 and December 31, 2015	28,355	52,328
Inventory	70,654	64,584
Prepaid expenses and other current assets	18,006	19,995
Current assets held for sale	0	322,837
Total current assets	717,371	832,917
Fixed assets, net	32,450	34,780
Intangible assets, net	621,690	636,220
Goodwill	255,629	289,441
Restricted cash	5,050	1,428
Contingent purchase price from sale of businesses	143,700	0
Other assets	743	730
Total assets	1,776,633	1,795,516
Current liabilities:
Accounts payable	18,734	36,038
Accrued expenses	81,531	128,558
Current portion of contingent purchase price	39,800	26,800
Convertible senior notes	53,054	255,473
Deferred revenue	14,139	19,863
Current liabilities held for sale	0	67,515
Total current liabilities	207,258	534,247
Contingent purchase price	89,610	96,957
Convertible senior notes	617,490	312,107
Deferred tax liabilities	88,350	89,996
Other liabilities	10,879	13,346
Total liabilities	1,013,587	1,046,653
Equity component of currently redeemable convertible senior notes	1,641	17,089
Stockholders’ equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value per share, 187,500,000 authorized; 72,983,092 issued and 70,790,110 outstanding at September 30, 2016 and 71,767,371 issued and 69,574,389 outstanding at December 31, 2015	73	72
Additional paid-in capital	1,243,463	1,208,058
Treasury stock, at cost; 2,192,982 shares at September 30, 2016 and December 31, 2015	(50,000)	(50,000)
Accumulated deficit	(426,132)	(429,865)
Accumulated other comprehensive (loss) income	(5,484)	3,973
Total The Medicines Company stockholders’ equity	761,920	732,238
Non-controlling interest in joint venture	(515)	(464)
Total stockholders’ equity	761,405	731,774
Total liabilities and stockholders’ equity	$ 1,776,633	$ 1,795,516